{"id":"combigan-ophthalmic-solutiom","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular hyperemia"},{"rate":null,"effect":"Ocular pruritus"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Dry eye"},{"rate":null,"effect":"Allergic conjunctivitis"}]},"_chembl":{"chemblId":"CHEMBL4301898","moleculeType":"Small molecule","molecularWeight":"832.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine tartrate, the alpha-2 agonist component, selectively stimulates alpha-2 adrenergic receptors to reduce aqueous humor production and enhance uveoscleral outflow. Timolol maleate, the non-selective beta-blocker component, decreases aqueous humor production through inhibition of beta-adrenergic receptors. Together, these complementary mechanisms provide additive intraocular pressure reduction in glaucoma and ocular hypertension.","oneSentence":"Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:36.817Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT00442312","phase":"PHASE4","title":"Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy","status":"UNKNOWN","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2006-05","conditions":"Glaucoma","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Combigan Ophthalmic Solutiom","genericName":"Combigan Ophthalmic Solutiom","companyName":"Genovate Biotechnology Co., Ltd.,","companyId":"genovate-biotechnology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Combigan combines a beta-adrenergic antagonist and an alpha-2 adrenergic agonist to reduce intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}